Skip to main content

Seborrheic Keratosis

1
Pipeline Programs
2
Companies
17
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Aclaris Therapeutics
Aclaris TherapeuticsMO - St. Louis
1 program
1
A-101Phase 35 trials
Active Trials
NCT03812510Completed426Est. Dec 2019
NCT03687372Completed503Est. Sep 2019
NCT03691831Completed502Est. Jul 2019
+2 more trials
DermBiont
DermBiontMA - Boston
2 programs
SM-020PHASE_21 trial
SM-020 gel 1.0%PHASE_21 trial
Active Trials
NCT05136144Unknown70Est. Jul 2024
NCT06108024Recruiting60Est. Oct 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Aclaris TherapeuticsA-101
Aclaris TherapeuticsA-101
Aclaris TherapeuticsA-101
Aclaris TherapeuticsA-101
Aclaris TherapeuticsA-101
Aclaris TherapeuticsA-101
Aclaris TherapeuticsA-101
DermBiontSM-020 gel 1.0%
DermBiontSM-020
Aclaris TherapeuticsA-101
Aclaris TherapeuticsA-101
Aclaris TherapeuticsA-101
Aclaris TherapeuticsA-101
Aclaris TherapeuticsA-101
Aclaris TherapeuticsA-101

Showing 15 of 17 trials with date data

Clinical Trials (17)

Total enrollment: 3,718 patients across 17 trials

An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses

Start: Mar 2018Est. completion: Nov 201841 patients
Phase 4Completed

Safety Study of A-101 Topical Solution for the Treatment of Common Warts

Start: Feb 2019Est. completion: Dec 2019426 patients
Phase 3Completed

Study of A-101 Topical Solution for the Treatment of Common Warts

Start: Sep 2018Est. completion: Sep 2019503 patients
Phase 3Completed

A Study of A-101 Topical Solution for the Treatment of Common Warts

Start: Sep 2018Est. completion: Jul 2019502 patients
Phase 3Completed

An Open-Label Safety Study of A-101 Solution

Start: Jan 2016Est. completion: Oct 2016147 patients
Phase 3Completed

A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis

Start: Jan 2016Est. completion: Oct 2016487 patients
Phase 3Completed

A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.

Start: Jan 2016Est. completion: Oct 2016450 patients
Phase 3Completed
NCT06108024DermBiontSM-020 gel 1.0%

A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis

Start: Nov 2023Est. completion: Oct 202460 patients
Phase 2Recruiting

Adaptive Design Study for Safety and Efficacy of Treatment Regimens With SM-020 in Subjects With Seborrheic Keratosis

Start: Oct 2021Est. completion: Jul 202470 patients
Phase 2Unknown

A Phase2 of A-101 Topical Solution in Subjects With Common Warts

Start: Aug 2017Est. completion: Mar 2018157 patients
Phase 2Completed

A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts

Start: Jul 2017Est. completion: Mar 2018159 patients
Phase 2Completed

A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra

Start: Jun 2017Est. completion: Jan 201939 patients
Phase 2Completed

A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis

Start: May 2017Est. completion: Apr 2018253 patients
Phase 2Completed

A Study of A-101 Solution in Subjects With Common Warts.

Start: Dec 2015Est. completion: Sep 201698 patients
Phase 2Completed

Study of A-101 for the Treatment of Seborrheic Keratosis

Start: Oct 2014Est. completion: Mar 2015119 patients
Phase 2Completed

Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis

Start: Jun 2014Est. completion: Dec 2014172 patients
Phase 2Completed

Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis

Start: Oct 2013Est. completion: Feb 201435 patients
Phase 1/2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 3,718 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.